VivoSeq
Infectious Disease

HIV Infection

283

Pipeline Programs↗

15

Active Trials↗

77

Companies Involved↗

HIV infection is a highly competitive landscape with 283 programs across 77 companies. The most active players are Elim Pediatric Pharmaceuticals Inc., Zeria Pharmaceutical, Salix. 102 therapies are approved with 40 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

85/100

Pipeline Velocity

19/100

Mech. Concentration

8/100

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Elim Pediatric Pharmaceuticals Inc.

2 programs

Phase 1Z

Zeria Pharmaceutical

1 program

Phase 1S

Salix

1 program

Phase 1I

Immunex

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1G

Genzyme, a Sanofi Company

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical28

Tenofovir

GSK

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Testosterone

Auxilium

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Nelfinavir Mesylate

Agouron Pharmaceuticals

Phase 149

Hydroxychloroquine

Alnylam Pharmaceuticals

Cemiplimab

Regeneron

DARUNAVIR

Wim Janssens

Rifaximin

Salix

Levofloxacin

Wim Janssens

Phase 264

Tremelimumab

AstraZeneca

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Etoricoxib

Novartis

Calcium Carbonate

Otsuka

Palifermin

Swedish Orphan Biovitrum

Phase 340

Aldesleukin

Iovance Biotherapeutics, Inc.

Interferon Beta-1b

Bayer

Sargramostim

Sanofi

Peginterferon Alfa-2b

Merck & Co.

Megestrol Acetate

Bristol-Myers Squibb

Approved102

Panobinostat

SecuraBio

Baricitinib

Eli Lilly

Ganciclovir

Exela Pharma Sciences, LLC.

Ritonavir

AbbVie

Fluconazole

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Analysis

Modality Breakdown

91%

Small molecule

262 of 288 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody124%Protein / enzyme72%Vaccine41%Peptide2<1%Cell therapy1<1%

Small molecule leads; the ring shows all 288 classified programs, each share of the total. Modality classified for 99% of 327 pipeline programs.

Analysis

Trial Status

208

clinical trials

Completed152 · 73%
Unknown status17 · 8%
Terminated14 · 7%
Recruiting7 · 3%
Withdrawn6 · 3%
Active, not recruiting4 · 2%
Other8 · 4%

Clinical Trials

Trial Activity

208 trials

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05719441·48 enrolled
Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection
Recruiting·UUniversity Hospital, Ghent·N/A·NCT03449706·70 enrolled
Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants
Recruiting·CCode Pharma·Phase 2·NCT06676410·40 enrolled
Antiretroviral Therapy for Acute and Chronic HIV Infection
Recruiting·SSEARCH Research Foundation·Phase 3·NCT00796263·900 enrolled
CAR-T Cells for HIV Infection
Recruiting·—·Phase 1/2·NCT04648046·18 enrolled
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up
Recruiting·IInstituto Mexicano del Seguro Social·Approved·NCT07678268·78 enrolled
Dental Management of Patients Living With HIV: A Retrospective Study Using COREVIH Data in Pays de la Loire
Recruiting·NNantes University Hospital·N/A·NCT07552038·5,603 enrolled
Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection
Active, not recruiting·TThai Red Cross AIDS Research Centre·Phase 2·NCT04505501·14 enrolled
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
Active, not recruiting·Gilead logoGilead·Phase 3·NCT04994509·5,368 enrolled
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
Active, not recruiting·PPENTA Foundation·Phase 2/3·NCT04337450·386 enrolled
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
Active, not recruiting·UUniversity of California, San Francisco·Phase 4·NCT02656511·74 enrolled
An Open-label Randomized Trial Evaluating the Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Preclinical·NCT07695493·504 enrolled
Retrospective/Prospective Pilot Study to Evaluate Efficacy and Safety of Switching to BIC/FTC/TAF in PWH With a Previous Virological Failure Under CAB/RPV LAI
Not yet recruiting·—·N/A·NCT07620652·30 enrolled
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV PrEP and STI PEP for Young Men
Not yet recruiting·HHIV Prevention Trials Network·Phase 3·NCT07658976·400 enrolled
Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis
Enrolling by invitation·HHospitales Universitarios Virgen del Rocío·N/A·NCT05492565·500 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)